Xencor (NASDAQ:XNCR) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Xencor (NASDAQ:XNCR) from a sell rating to a hold rating in a research report released on Thursday.

Several other research analysts also recently issued reports on XNCR. Wells Fargo & Company lowered their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. JPMorgan Chase & Co. upped their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $34.38.

Xencor Stock Performance

Xencor stock opened at $13.85 on Thursday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $975.90 million, a PE ratio of -4.33 and a beta of 0.75. Xencor has a 12-month low of $13.42 and a 12-month high of $27.24. The business’s 50-day moving average price is $18.60 and its two-hundred day moving average price is $20.58.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, analysts expect that Xencor will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Xencor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XNCR. GAMMA Investing LLC lifted its position in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the period. KBC Group NV raised its stake in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 949 shares during the period. Sterling Capital Management LLC boosted its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its holdings in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 1,282 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.